Completed PHASE1 INTERVENTIONAL 2-arm NCT03206229

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects (TPI-120)

A Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study Comparing TPI-120 and Neulasta® Administered Through Subcutaneous Route in Healthy Adult Subjects

Sponsor: Adello Biologics, LLC

Conditions Healthy Volunteers

Interventions Neulasta (PEG-rhG-CSF) PEG-rhG-CSF

Updated 6 times since 2017 Last updated: Jul 2, 2018 Started: Feb 13, 2017 Primary completion: Jun 2, 2017 Completion: Jan 18, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers and is currently completed. Adello Biologics, LLC leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Feb 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adello Biologics, LLC
inVentiv Health Clinical

Data source: Adello Biologics, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cypress, United States